Dequonal may be part of a supportive management strategy across two distinct therapeutic domains.

Easing Localized Discomfort and Symptom Burden

Dequonal may be commonly used in situations involving distressing symptoms of localized infectious vaginitis, including bacterial vaginosis and vaginal candidiasis (thrush). It is also relevant for easing symptoms that create noticeable physiological strain in the oro-pharyngeal cavity, often associated with conditions like tonsillitis, pharyngitis (sore throat), and oral thrush. Applied across conditions characterized by periods of heightened symptoms, this approach provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort.

Clinical use is considered relevant in contexts involving heightened systemic burden, such as scenarios surrounding minor gynecological procedures. The medication may assist with maintaining functional stability for patient groups including women of childbearing age.

---

Quick Fact: Supports Management of Acute Symptomatic Episodes

The medication is commonly used when symptoms intensify, offering supportive symptomatic relief for conditions involving episodic or recurrent manifestations across both the vaginal and oro-pharyngeal sites.

---

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA)

The eligibility for Dequonal (Dequalinium Chloride) is defined by its specific delivery form and set forth by regulatory authorities across different regions.

Eligibility Scope

Category	Population/Condition (As Stated in Regulatory Label)
Populations Contraindicated	Hypersensitivity to the active substance or excipients.
	Ulceration of the vaginal epithelium and portio vaginalis uteri (for vaginal ovules).
	Pre-menarcheal young girls (prohibited for vaginal ovules).
Age-Related Rules	Adults are the primary established population for both forms (vaginal and oro-pharyngeal).
	Not established in women under 18 or over 55 years due to insufficient safety/efficacy data (vaginal ovules).
	Children over 10 or 12 years are permitted to use lozenges (minimum age varies by specific product).
Pregnancy/Lactation Status	Use may be considered during pregnancy and lactation due to negligible systemic exposure.
Eligibility-Related Restrictions	Do not use within 12 hours before expected birth (vaginal ovules).

Eligibility Classifications (High-Level)

The official documents define the eligibility profile through strict classifications:

• Contraindication: Absolute prohibition for groups such as pre-menarcheal girls and patients with specific local tissue damage (ulceration) at the application site.
• Conditional Use: Permitted during pregnancy and lactation, but with a restriction on use immediately prior to delivery.
• Use Not Established: Noted for women under 18 and over 55 years due to a lack of complete clinical data on efficacy and safety in these age ranges.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by setting absolute prohibitions based on local tissue status (ulceration) and immunological history (hypersensitivity). Eligibility is further structured by age limitations and explicitly restricted for use immediately prior to birth, ensuring adherence to officially documented parameters for patient eligibility.

Interactions with other medicines and products

Dequonal (Dequalinium Chloride) is formulated as a local anti-infective agent for topical application, resulting in minimal systemic exposure. Consequently, the drug’s official interaction profile focuses on local chemical interference and administration-timing requirements rather than systemic pharmacokinetic interactions.

---

Documented Local Interactions and Restrictions

Interaction Type	Interacting Substance/Class	Official Restriction
Local Chemical Inactivation	Anionic surfactants (e.g., soaps, detergents)	Strictly Contraindicated for co-administration.
Administration Timing	Vaginal lavage or douches	Use is advised against concurrently during treatment.

Contraindicated Combinations

The co-administration of Dequonal with any substance containing an anionic surfactant, such as soaps or detergents, is officially contraindicated. This is a specific chemical prohibition to prevent the anionic agent from inactivating the cationic active ingredient at the application site, which would render the treatment ineffective.

Timing-Based Constraints

The regulatory label requires that the use of vaginal lavage or vaginal douches be avoided concurrently during the course of treatment. This restriction is in place to prevent physical interference with the local delivery and activity of the medicine.

Absence of Systemic Interactions

Regulatory documents contain no officially documented interactions involving major metabolic enzymes, such as the CYP450 system, drug transporters, food, alcohol, or herbal products. This finding is consistent with the minimal systemic absorption of the active ingredient from the localized route of administration.

Cationic Surfactant Destroys Microbial Cell Integrity

The primary mechanism of Dequalinium Chloride involves its action as a cationic surfactant, which rapidly engages the negatively charged microbial cell membrane of bacteria and fungi. This strong electrostatic binding physically destabilizes the lipid bilayer, causing the formation of pores and the immediate, uncontrolled efflux of essential intracellular components. This structural collapse results in rapid, irreversible microbial cell death, leading to localized reduction of pathogenic microbial load.

---

Metabolic and Genetic Inhibition (Secondary Action)

The action is augmented by the subsequent entry of the drug into the cell's interior following membrane breach. Once inside, Dequalinium Chloride causes the inhibition of vital metabolic enzymes (such as F1-ATPase) required for energy production and precipitates the pathogen's nucleic acids (DNA/RNA). This simultaneous interference with the microbial energy supply and replication capacity ensures irreversible cellular damage and contributes to the drug's broad-spectrum bactericidal and fungicidal activity at the application site.

---

Localized Action and Mechanistic Constraints

The physical and chemical properties of the molecule confine its mechanism strictly to the mucosal surface, resulting in a localized anti-infective activity pattern due to poor systemic absorption. While effective across a broad spectrum, the mechanism exhibits differential sensitivity, often proving more lethal to Gram-positive bacteria than to Gram-negative types due to structural differences in their cell envelopes.

How to use Dequonal: Administration Guidelines

Dequonal (Dequalinium Chloride) is an anti-infective agent designed for local application. Its use is characterized by defined parameters regarding the route, dose, and administration technique for each specific dosage form. These parameters ensure standardized use.

---

Routes and Dosage Forms

Feature	Administration Principle
Route of Administration	Topical/Local (Vaginal or Oromucosal)
Vaginal Dosage Form	Vaginal Ovule (10 mg Dequalinium Chloride)
Oromucosal Dosage Forms	Lozenge or Throat Spray

---

Standard Dosing Regimens and Procedures

The usage protocol for Dequonal depends on the site of application. The following parameters are based on standard prescribing information.

Vaginal Ovules (10 mg)

• Dose and Frequency: One 10 mg ovule is inserted once daily.
• Timing: Administration is preferably done in the evening before lying down.
• Course Duration: The course duration is 6 days, and this treatment is not interrupted, even during menstruation.
• Technique: The ovule is inserted deeply into the vagina. The ovule may be moistened with water before insertion to ease placement.
• Population: Use is specified for adult women.

Oromucosal Preparations (Lozenges)

• Dose and Frequency: One lozenge is used per administration, typically every 2 to 3 hours as needed.
• Maximum Dose: The recommended maximum dose is 8 lozenges in a 24-hour period.
• Technique: The lozenge must be sucked slowly in the mouth; it should not be chewed or swallowed whole.

The administration method is strictly local, establishing a defined course of treatment for the 10 mg ovule that is completed according to the established daily schedule and technique.

Research Evidence / Overview of Studies for Dequonal

The clinical evaluation of Dequalinium Chloride (Dequonal) is structured around studies that have examined the compound in specific localized applications. The research landscape is divided based on its specific delivery forms: studies for vaginal infections and research related to oro-pharyngeal use.

---

Evidence for Vaginal Infections (Bacterial Vaginosis and Candidiasis)

The core evidence base includes studies that explore the role of Dequonal for conditions like Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC). This evidence is derived from Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Researchers conducted non-inferiority trials. These are a type of study exploring whether the medicine performs similarly to established treatments like certain oral or vaginal antibiotics.

Research examined multiple outcomes related to physical discomfort and biological changes. Researchers monitored for clinical cure rates (a measurement endpoint defined by the full reversal of diagnostic signs), and they tracked symptom changes, such as shifts in discharge or odor. Studies reported measurements of outcomes that were observed in trials designed to explore whether the compound performed similarly to standard prescription therapies used in the non-inferiority trials.

However, the research also describes certain limitations. There is limited information for long-term outcomes regarding how often infections recur after the treatment period. Furthermore, some research has noted mixed findings between the reported changes in physical discomfort and sustained microbiological clearance in conditions like VVC.

---

Evidence for Oro-pharyngeal Infections (Sore Throat and Mouth Infections)

The research context for Dequonal's use in the throat and mouth—for conditions like pharyngitis or minor stomatitis—has a different focus than the vaginal studies. Evidence is primarily derived from data on the compound’s general properties as a broad-spectrum antiseptic agent used in observational settings. Research focused on outcomes related to acute changes during periods of heightened symptom activity, such as the degree of localized soreness or inflammation.

The key research limitation is that comparative evidence is lacking from large, recent studies against placebos or alternative treatments for specific, measurable clinical metrics, such such as standardized pain scores. The evidence level for this use may be considered low, as the current understanding appears to be largely extrapolated from the drug’s general anti-infective properties.

Key Studies & References

1. Dequalinium chloride 10 mg vaginal tablets Summary of Product Characteristics (SPC)
2. Antiseptics and disinfectants: mechanism of action and clinical application

Common questions about Dequonal (FAQ)

---

Q: What makes Dequonal different from other similar treatments?

Official product information describes Dequonal's unique mechanism as a cationic surfactant. This works by rapidly and irreversibly destabilizing the microbial cell membrane of bacteria and fungi, rather than relying solely on metabolic inhibition. Regulatory documents describe the active ingredient's profile as having a broad spectrum of activity against various pathogens at the application site.

---

Q: Are there any common mild side effects people experience with Dequonal?

Official product information states that common reactions are localized to the application site. These may include a burning sensation, itching (pruritus), pain, and discharge. Official product information notes that these local effects are more commonly observed at the beginning of treatment.

---

Q: Can Dequonal be used by children, and if so, at what age?

Eligibility depends on the specific product form. Regulatory guidelines state that the vaginal ovule form is not established for those under 18 and is contraindicated (prohibited) for pre-menarcheal young girls. Conversely, lozenge forms are typically permitted for children over the age of 10 or 12 years, according to the specific product label.

---

Q: Is Dequonal safe for elderly patients?

For the vaginal ovule formulation, official regulatory data notes that safety and effectiveness are not established for women over 55 years of age due to insufficient data. For the lozenge formulations, there are typically no specific dosage restrictions related to age for the elderly population.

---

Q: Why do some people say Dequonal works really well for them, while others don't notice a difference?

Official pharmacological data suggests this variability may be related to the drug's mechanism of action. The mechanism is noted to show differential sensitivity, often proving more lethal to Gram-positive bacteria than to Gram-negative types. The drug's effectiveness is also established based on achieving a maximum local concentration soon after application.

---

Q: How long does a dose of Dequonal stay in your system?

Because Dequonal is formulated for local application (e.g., vaginal or throat), regulatory studies show that systemic absorption into the bloodstream is minimal or negligible. Therefore, detailed information about how long the drug remains in the systemic circulation is generally not available, as its action is confined to the application site.

---

Q: Are there any specific lifestyle changes recommended while taking Dequonal?

Official regulatory documents advise against the concurrent use of vaginal lavage or douches, as these may interfere with the medicine's local activity. The product information may also note that when using vaginal tablets, it is advised to change and launder underwear and flannels daily at a high temperature.

---

Q: Is it possible to develop a tolerance to Dequonal over time?

Official pharmacological studies indicate that for Dequalinium Chloride, the active ingredient, no mechanisms of acquired resistance (where the microbes become tolerant to the drug) have been observed to date.

---

Q: Does Dequonal have a strong taste or smell?

The active compound, Dequalinium Chloride, is often described in regulatory material as an odourless powder with a bitter taste. The lozenge formulations contain inactive ingredients and flavorings which help mask the bitter taste of the active compound.

---

Q: What are the typical storage instructions for Dequonal?

Official product information requires that Dequonal be stored below 25 C and kept in its original packaging, protected from heat and moisture. Furthermore, official instructions require that unused or expired medicine must not be disposed of in household waste or via wastewater, and patients are directed to ask a pharmacist for disposal guidance.

---

Q: Can pregnant women or those who are breastfeeding use Dequonal?

Due to the negligible systemic absorption of the drug, its use may be considered during pregnancy and breastfeeding. However, a specific warning in the regulatory label states that the vaginal tablet formulation must not be used within 12 hours before expected birth.

---

Q: Does Dequonal have different formulations for adults versus children?

The medicine is available in forms tailored to different application sites (vaginal ovules and lozenges). For the lozenge form, the active ingredient strength is usually consistent, but the difference in use is governed by age-specific restrictions and the maximum daily quantity permitted.

The storage and disposal instructions for Dequonal (Dequalinium Chloride) are strictly defined in official regulatory documents to ensure product stability and environmental safety.

Storage Conditions

The product must be stored below 25 C (77 F) and must be protected from heat and moisture. To maintain its 3-year shelf-life, the medicine should be kept in the original package.

Requirement	Official Instruction
Temperature	Store below 25 C (77 F)
Protection	Protect from heat and moisture
Packaging	Keep in the original package
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

To help protect the environment, unused or expired Dequonal must not be thrown away via wastewater or household waste. Users are instructed to ask a pharmacist for guidance on how to properly discard the medicine.